Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
about
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptideStructure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPYThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingIdentification of myxomaviral serpin reactive site loop sequences that regulate innate immune responsesSelective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammationUrokinase-type plasminogen activator supports liver repair independent of its cellular receptorMapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.Cellular strategies for proteolytic targeting during migration and invasion.Mutant laboratory mice with abnormalities in hair follicle morphogenesis, cycling, and/or structure: annotated tables.c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptasePlasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpressionUrokinase and its receptors in chronic kidney disease.Molecular mechanisms of glioma invasiveness: the role of proteases.MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.Proteolytic networks in cancerIntact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.Involvement of urokinase-type plasminogen activator system in cancer: an overview.The cleavage of the urokinase receptor regulates its multiple functions.Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism.New developments in the urokinase-type plasminogen activator system.Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction.Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
P2860
Q24529128-44E0ACEA-AAE0-422B-BFE0-E1A68CC593F4Q27659603-9130277E-AF06-4E26-AC43-B51350C67EC4Q28257803-FE05AC79-BA33-4D97-A4DD-F2DF511AB83EQ28291150-39181557-7DB4-4A1F-80D3-F33E1B1FEE55Q30496585-04C7292F-26D6-4E8F-94B9-410589DF57DDQ33264968-86FB2D35-2849-4D59-9D11-91E677CFC61DQ33278178-D334D3C0-52CE-47A3-9A0F-BB160AD93245Q33917709-856B2107-B62D-4B10-9990-90C0CF764453Q34009345-5CC9F1ED-489A-4784-A4E0-5B29769AEA87Q34145178-CEE6065C-6239-46E4-8C55-D60DBC71B8CDQ34157183-55BEE9E5-547E-4F9E-ADD2-6FEDE5FEA155Q34395533-D2752015-405F-4FFB-818D-CDF40B8C7BE8Q34459252-A3E58C07-84A9-44F9-BA5F-E44A4667DE3AQ34883707-E63F4518-30C6-4621-9E1B-8C4F2A4545A7Q35098346-6BE5FFDB-F0E8-4BA4-A781-27D13FB9B685Q35124141-53B1934A-C219-4B4F-9D0B-E7AFAC61B4A5Q35166808-D2E127CD-80E3-4880-9261-D2B4C342047CQ35953723-B27C8219-E46D-47EF-B37A-6450CCF41127Q37343319-00B4EE09-5260-43B5-B58F-D66079FE8B2DQ37345362-958C1401-DA37-48DE-95A1-7839B70494ECQ38132176-307EA59C-8BC9-49AF-9B57-ADA94ACE0563Q38189275-4468802E-C074-47B7-9438-1E0D418E58CFQ40701611-68F28EB6-E731-4078-9075-0B3BF3476600Q40872425-AF5D3194-7DF9-4455-83A2-4D2AF26C2BC9Q43000092-3465E272-9EDB-4806-9B0F-5575F7043699Q43002806-F2862FDC-D457-4245-992D-5C5CD25244E6Q43591840-26BBCB0B-E6F7-4A20-AEAD-2ACB110CB6EEQ46025949-4C2BC3C3-4A79-4567-B453-F3A41C1C9A7AQ46609756-9F9AA826-AA17-4690-938D-D16EE87220DFQ52956238-A96E0C34-A1B2-4AE3-B726-FEB01AAE9849
P2860
Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@ast
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@en
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@nl
type
label
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@ast
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@en
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@nl
prefLabel
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@ast
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@en
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@nl
P2093
P2860
P356
P1433
P1476
Urokinase-type plasminogen act ...... romote pathogenic proteolysis.
@en
P2093
P2860
P304
P356
10.1093/EMBOJ/19.17.4817
P407
P577
2000-09-01T00:00:00Z